Pedram Hendizadeh
Foot Surgery · Manhasset, NYNPI 1780786517
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,098 of the $6,467 with a category attached, or 63.4%. It is spread thinly across 37 manufacturers, the largest accounting for just 21.5%. Reporting peaked in 2021 at $2,735 and has fallen 73.2% since, to $732 in 2025. Among foot surgery clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $59.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$1K
- Stryker$1K
- Gramercy Extremity Orthopedics LLC$933
- Treace Medical Concepts, Inc.$554
- Gotham Surgical Solutions & Devices, Inc.$354
- DJO, LLC$302
- plus $2K from 31 others
What the payments were for
- Consulting fees$66610%
- Travel & lodging$5028%
- Food & beverage$4,09863%
- Education$1,20019%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 6 | $1,388 |
| Stryker(2 entities) | 14 | $1,034 |
| Gramercy Extremity Orthopedics LLC | 2 | $933 |
| Treace Medical Concepts, Inc. | 11 | $554 |
| Gotham Surgical Solutions & Devices, Inc. | 2 | $354 |
| DJO, LLC | 10 | $302 |
| Amgen | 6 | $166 |
| Smith+Nephew | 4 | $164 |
| Osiris Therapeutics Inc. | 2 | $163 |
| Royal Biologics, Inc. | 3 | $160 |
| Orthofix Medical, Inc. | 5 | $148 |
| GRT US Holding, Inc. | 5 | $113 |
| Dynasplint Systems Inc. | 2 | $104 |
| Nevro Corp. | 2 | $89 |
| Medtronic(2 entities) | 4 | $84 |
| Triad Life Sciences Inc. | 1 | $73 |
| Merck | 4 | $62 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $55 |
| Osteomed LLC | 2 | $50 |
| Vertex | 2 | $48 |
| Zimmer Biomet | 1 | $48 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $44 |
| Paratek Pharmaceuticals, Inc. | 2 | $40 |
| Sebela Pharmaceuticals Inc. | 2 | $34 |
| AbbVie | 1 | $27 |
| Next Science LLC | 1 | $25 |
| Globus Medical | 1 | $24 |
| Integra Lifesciences Corporation | 1 | $23 |
| Journey Medical Corporation | 1 | $23 |
| Sandoz | 1 | $23 |
| Baudax Bio Inc. | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Tactile Systems Technology Inc | 1 | $15 |
| Medline Industries LP | 1 | $15 |
| Arthrosurface Incorporated | 1 | $14 |
| Fidia Pharma USA Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ASNIS$474
- ANCHORAGE$311
- AUGMENT INJECTABLE$273
- SUBFIX$169
- VARIAX$163
- Lapiplasty System$160
- SMART TOE$142
- ORTHOLOC 2 LAPIFUSE$110
- SWANSON$110
- SALVATION$102
- PROPHECY$102
- VALOR$102
- Stravix$100
How this compares
$6,467 in reported general payments places this provider in the 90th percentile of 294 foot surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JubliaEfinaconazole | 14 | $20,364 |
| Terbinafine Hcl | 24 | $201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia | $44 | $20,36414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 294 foot surgery providers in New York.
Other foot surgery in Manhasset
- Ronald GubermanRidgewood$337K
- John JackaloneBethpage$66K
- David WongBronx$45K
- Berdj StepanianWhite Plains$26K
- Lawrence SantiBrooklyn$25K
- David GitlinBayside$24K
- Rick DelmonteNew York$21K
- Corrine RenneFranklin Square$20K
- Charles MorelliMamaroneck$18K
- Evan BrethBrooklyn$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.